tradingkey.logo

Nautilus Biotechnology Inc <NAUT.OQ> expected to post a loss of 16 cents a share - Earnings Preview

ReutersFeb 25, 2025 1:46 PM
  • Nautilus Biotechnology Inc NAUT.OQ NAUT.O is expected to show no change in quarterly revenue when it reports results on February 27 for the period ending December 31 2024

  • ​LSEG's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 16 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $3.00​, above​ its last closing price of $1.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.16

-0.16

-0.13

Beat

21.2

Jun. 30 2024

-0.16

-0.16

-0.14

Beat

14.6

Mar. 31 2024

-0.17

-0.16

-0.15

Beat

7.7​

Dec. 31 2023

-0.13

-0.14

-0.14

Met

3.4

​​Sep. 30 2023

-0.17

-0.17

-0.13

Beat

22.4

Jun. 30 2023

-0.14

-0.15

-0.13

Beat

13.3​

Mar. 31 2023

-0.16

-0.17

-0.12

Beat

28

Dec. 31 2022

-0.14

-0.15

-0.11

Beat

28.3

This summary was machine generated February 25 at 13:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI